Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Cue Biopharma presents T-cell modulatory antigen-presenting polypeptides

Sep. 29, 2020

Millendo begins first-in-human study of MLE-301 for vasomotor symptoms in menopausal women

Sep. 25, 2020

New phase II study evaluates encaleret for autosomal dominant hypocalcemia type 1

Sep. 22, 2020

Bristol-Myers Squibb presents new MGAT2 inhibitors

Sep. 22, 2020

Discovery of novel potent and orally bioavailable SGLT1 and SGLT2 dual inhibitors

Sep. 21, 2020

First-in-human study of progerinin

Sep. 21, 2020

Enrollment ongoing in phase I study of INV-101

Sep. 17, 2020

CAEL-101 enters phase III program for AL amyloidosis

Sep. 15, 2020

Phase IIb topline results for Diamyd in type 1 diabetes

Sep. 15, 2020

Galapagos discloses PASK inhibitors

Sep. 14, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
New schizophrenia targets challenge trial design
BioWorld
The search for better schizophrenia therapies is moving beyond dopamine toward a growing number of experimental targets. According to researchers, the repeated...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 28, 2026
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Fauci’s silence may put him in contempt of Congress
BioWorld
After repeatedly invoking the Fifth Amendment to every question asked during the July 29 hearing of the U.S. Senate Homeland Security Committee, Anthony Fauci,...